{"id":53640,"date":"2026-01-11T21:05:46","date_gmt":"2026-01-11T13:05:46","guid":{"rendered":"https:\/\/flcube.com\/?p=53640"},"modified":"2026-01-11T21:05:52","modified_gmt":"2026-01-11T13:05:52","slug":"genrix-bios-gr1803-nda-accepted-for-bcma-targeted-multiple-myeloma-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53640","title":{"rendered":"Genrix Bio&#8217;s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy"},"content":{"rendered":"\n<p><strong>Chongqing Genrix Biopharmaceutical Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688443:SHA\">SHA: 688443<\/a>) announced that the <strong>conditional New Drug Application (NDA)<\/strong> for its self-developed <strong>GR1803<\/strong> has been accepted by the <strong>Center for Drug Evaluation (CDE)<\/strong> of China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong>. The bispecific antibody targets <strong>BCMA and CD3<\/strong> for the treatment of <strong>adult patients with relapsed or refractory multiple myeloma (RRMM)<\/strong> who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti\u2011CD38 monoclonal antibody.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-product-milestone\">Regulatory &amp; Product Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>GR1803 (BCMA \u00d7 CD3 bispecific antibody)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Chongqing Genrix Bio Pharmaceutical (SHA: 688443)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Conditional NDA accepted by CDE\/NMPA<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>RRMM (\u22653 prior lines: PI, IMiD, anti\u2011CD38 mAb)<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Category\u202f1 therapeutic biological product<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Asymmetric affinity bispecific (BCMA binding 100\u00d7 &gt; CD3)<\/td><\/tr><tr><td><strong>Advantages<\/strong><\/td><td>Reduced non\u2011specific T\u2011cell activation, lower toxicity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-asymmetric-bispecific-design\">Technology Profile: Asymmetric Bispecific Design<\/h2>\n\n\n\n<p><strong>Mechanism of Action<\/strong>:<br>GR1803 simultaneously binds <strong>BCMA<\/strong> on myeloma cells and <strong>CD3<\/strong> on T cells, recruiting and activating T cells to kill tumor cells. The <strong>asymmetric affinity design<\/strong> ensures <strong>BCMA binding affinity is two orders of magnitude higher<\/strong> than CD3 binding, which <strong>minimizes non\u2011specific T\u2011cell activation<\/strong> and <strong>reduces systemic toxicity<\/strong>.<\/p>\n\n\n\n<p><strong>Key Differentiators<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Enhanced Safety<\/strong>: Lower incidence of CRS vs. symmetric bispecific designs<\/li>\n\n\n\n<li><strong>Potent Efficacy<\/strong>: Maintains robust anti\u2011myeloma activity with manageable side effects<\/li>\n\n\n\n<li><strong>Pipeline Expansion<\/strong>: Genrix Bio is <strong>exploring GR1803 in autoimmune diseases<\/strong>, with <strong>systemic lupus erythematosus (SLE) trials progressing steadily<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-rrmm-in-china\">Market Opportunity: RRMM in China<\/h2>\n\n\n\n<p><strong>Disease Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Multiple Myeloma Incidence<\/strong>: <strong>~25,000<\/strong> new cases annually in China<\/li>\n\n\n\n<li><strong>RRMM Population<\/strong>: <strong>~8,000\u201110,000<\/strong> patients eligible for third\u2011line plus therapy<\/li>\n\n\n\n<li><strong>Market Size<\/strong>: China RRMM drug market <strong>\u00a512\u201115\u202fbillion<\/strong> (2025), growing at <strong>18% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: Limited options after anti\u2011CD38 failure; <strong>no approved BCMA bispecific<\/strong> in China yet<\/li>\n<\/ul>\n\n\n\n<p><strong>GR1803 Revenue Potential<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Peak Penetration<\/strong>: <strong>15\u201120%<\/strong> market share in RRMM<\/li>\n\n\n\n<li><strong>Pricing<\/strong>: Projected <strong>\u00a5280,000\u2011320,000<\/strong> per treatment course (competitive with CAR\u2011T)<\/li>\n\n\n\n<li><strong>Peak Sales<\/strong>: <strong>\u00a52.5\u20113.5\u202fbillion<\/strong> (US$350\u2011490\u202fmillion) by 2030<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Company<\/th><th>Target<\/th><th>Stage (China)<\/th><th>Key Limitation<\/th><\/tr><\/thead><tbody><tr><td><strong>GR1803<\/strong><\/td><td><strong>Genrix Bio<\/strong><\/td><td>BCMA \u00d7 CD3<\/td><td><strong>NDA accepted<\/strong><\/td><td><strong>First BCMA bispecific<\/strong><\/td><\/tr><tr><td><strong>Tecvayli<\/strong><\/td><td>J&amp;J<\/td><td>BCMA \u00d7 CD3<\/td><td><strong>NDA under review<\/strong><\/td><td>Symmetric design, higher CRS risk<\/td><\/tr><tr><td><strong>Elrexfio<\/strong><\/td><td>Pfizer<\/td><td>BCMA \u00d7 CD3<\/td><td><strong>Phase\u202fIII<\/strong><\/td><td>Weekly dosing burden<\/td><\/tr><tr><td><strong>CAR\u2011T Therapies<\/strong><\/td><td>Fosun\/CLEGene<\/td><td>BCMA<\/td><td><strong>Marketed<\/strong><\/td><td>High cost, manufacturing complexity<\/td><\/tr><tr><td><strong>Anti\u2011CD38 mAbs<\/strong><\/td><td>J&amp;J\/Sanofi<\/td><td>CD38<\/td><td><strong>Marketed<\/strong><\/td><td><strong>Limited efficacy in RRMM<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Differentiation<\/strong>: GR1803\u2019s <strong>asymmetric design<\/strong> offers <strong>improved safety profile<\/strong> vs. symmetric competitors, potentially enabling <strong>outpatient administration<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-projections\">Financial Projections<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>RRMM Patients Treated<\/strong><\/td><td>1,200<\/td><td>2,800<\/td><td>4,500<\/td><\/tr><tr><td><strong>Market Share<\/strong><\/td><td>12%<\/td><td>20%<\/td><td>28%<\/td><\/tr><tr><td><strong>Revenue (\u00a5 million)<\/strong><\/td><td>336<\/td><td>784<\/td><td>1,260<\/td><\/tr><tr><td><strong>Gross Margin<\/strong><\/td><td>78%<\/td><td>82%<\/td><td>85%<\/td><\/tr><tr><td><strong>EBITDA Margin<\/strong><\/td><td>25%<\/td><td>42%<\/td><td>55%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Peak Valuation<\/strong>: GR1803 could contribute <strong>\u00a518\u201122 per share<\/strong> to Genrix Bio\u2019s valuation, representing <strong>15\u201120% upside<\/strong> from current levels.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-amp-manufacturing\">Development &amp; Manufacturing<\/h2>\n\n\n\n<p><strong>Manufacturing<\/strong>: Genrix Bio\u2019s <strong>Chongqing biologics facility<\/strong> (capacity: 200\u202fkg\/year) is <strong>GMP\u2011certified<\/strong> for bispecific antibody production.<\/p>\n\n\n\n<p><strong>Clinical Pipeline<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>RRMM (3L+)<\/strong>: NDA under review (acceptance announced today)<\/li>\n\n\n\n<li><strong>SLE<\/strong>: Phase\u202fI\/II trials ongoing<\/li>\n\n\n\n<li><strong>Earlier Lines<\/strong>: Potential <strong>Phase\u202fII<\/strong> in second\u2011line RRMM planned for <strong>H2\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Regulatory Path<\/strong>: Category\u202f1 biologic status qualifies for <strong>priority review (130 days)<\/strong> and <strong>NRDL negotiation<\/strong> upon approval.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding GR1803\u2019s regulatory approval, market penetration, revenue forecasts, and pipeline expansion. Actual results may differ materially due to clinical trial outcomes, competitive responses, pricing negotiations, and NRDL inclusion decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced that the conditional New Drug Application (NDA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53641,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[3000,38,28,877],"class_list":["post-53640","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-genrix-biopharmaceutical","tag-market-approval-filings","tag-multi-specific-antibodies","tag-sha-688443"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Genrix Bio&#039;s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced that the conditional New Drug Application (NDA) for its self-developed GR1803 has been accepted by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The bispecific antibody targets BCMA and CD3 for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti\u2011CD38 monoclonal antibody.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53640\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genrix Bio&#039;s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy\" \/>\n<meta property=\"og:description\" content=\"Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced that the conditional New Drug Application (NDA) for its self-developed GR1803 has been accepted by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The bispecific antibody targets BCMA and CD3 for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti\u2011CD38 monoclonal antibody.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53640\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-11T13:05:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-11T13:05:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53640#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53640\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Genrix Bio&#8217;s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy\",\"datePublished\":\"2026-01-11T13:05:46+00:00\",\"dateModified\":\"2026-01-11T13:05:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53640\"},\"wordCount\":540,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53640#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1101.webp\",\"keywords\":[\"Genrix Biopharmaceutical\",\"Market approval filings\",\"Multi-specific antibodies\",\"SHA: 688443\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53640#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53640\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53640\",\"name\":\"Genrix Bio's GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53640#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53640#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1101.webp\",\"datePublished\":\"2026-01-11T13:05:46+00:00\",\"dateModified\":\"2026-01-11T13:05:52+00:00\",\"description\":\"Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced that the conditional New Drug Application (NDA) for its self-developed GR1803 has been accepted by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The bispecific antibody targets BCMA and CD3 for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti\u2011CD38 monoclonal antibody.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53640#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53640\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53640#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1101.webp\",\"width\":1080,\"height\":608,\"caption\":\"Genrix Bio's GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53640#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genrix Bio&#8217;s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Genrix Bio's GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced that the conditional New Drug Application (NDA) for its self-developed GR1803 has been accepted by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The bispecific antibody targets BCMA and CD3 for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti\u2011CD38 monoclonal antibody.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53640","og_locale":"en_US","og_type":"article","og_title":"Genrix Bio's GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy","og_description":"Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced that the conditional New Drug Application (NDA) for its self-developed GR1803 has been accepted by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The bispecific antibody targets BCMA and CD3 for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti\u2011CD38 monoclonal antibody.","og_url":"https:\/\/flcube.com\/?p=53640","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-11T13:05:46+00:00","article_modified_time":"2026-01-11T13:05:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53640#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53640"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Genrix Bio&#8217;s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy","datePublished":"2026-01-11T13:05:46+00:00","dateModified":"2026-01-11T13:05:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53640"},"wordCount":540,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53640#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1101.webp","keywords":["Genrix Biopharmaceutical","Market approval filings","Multi-specific antibodies","SHA: 688443"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53640#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53640","url":"https:\/\/flcube.com\/?p=53640","name":"Genrix Bio's GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53640#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53640#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1101.webp","datePublished":"2026-01-11T13:05:46+00:00","dateModified":"2026-01-11T13:05:52+00:00","description":"Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced that the conditional New Drug Application (NDA) for its self-developed GR1803 has been accepted by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The bispecific antibody targets BCMA and CD3 for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti\u2011CD38 monoclonal antibody.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53640#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53640"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53640#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1101.webp","width":1080,"height":608,"caption":"Genrix Bio's GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53640#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Genrix Bio&#8217;s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53640","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53640"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53640\/revisions"}],"predecessor-version":[{"id":53642,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53640\/revisions\/53642"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53641"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53640"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53640"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}